Expression of MAC30 in rectal cancers with or without preoperative radiotherapy

Oncology

Volumn 71, Issue 3-4, 2007, Pages 259-265

  Zhang, Zhi Yong ^a,c,d   Zhao, Zeng Ren ^c   Adell, Gunnar ^a   Jarlsfelt, Ingvar ^b   Cui, Yong Xing ^d   Kayed, Hany ^e   Kleeff, Jörg ^e   Wang, Ming Wei ^c   Sun, Xiao Feng ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Jonkoping Hospital   (Sweden)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d Thangshan Gongren Hospital   (China)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

MAC30; Radiotherapy; Rectal cancer

Indexed keywords

KI 67 ANTIGEN; MENINGIOMA ASSOCIATED PROTEIN 30; PHOSPHATASE; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LIVER REGENERATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 34548073039     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106449     Document Type: Article

References (23)

1. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL: Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ 1993;4:715-722.
2. Malhotra K, Luehrsen KR, Costello LL, Raich TJ, Sim K, Foltz L, Davidson S, Xu H, Chen A, Yamanishi DT, Lindemann GW, Cain CA, Madlansacay MR, Hashima SM, Pham TL, Mahoney W, Schueler PA: Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res 1999;27:839-847.
3. Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H, Buchler MW, Friess H: Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol 2004;19:1021-1031.
4. Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, Sun XF: Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol 2007;30:91-95.
5. Atalay A, Crook T, Ozturk M, Luluq IG: Identification of genes induced by BRCA1 in breast cancer cells. Biochem Biophys Res Commun 2002;299:839-846.
6. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D: DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225-2234.
7. Potapova O, Anisimov SV, Gorospe M, Dougherty RH, Gaarde WA, Boheler KR, Holbrook NJ: Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res 2002;62:3257-3263.
8. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-987.
9. Adell G, Zhang H, Evertsson S, Sun XF, Stal OH, Nordenskjold BA: Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer 2001;91:1870-1875.
10. Adell G, Zhang H, Jansson A, et al: Decreased tumour cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2001;50:659-663.
11. Adell G, Sun XF, Stal O, Klintenberg C, Sjodahl R, Nordenskjold B: p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51:169-174.
12. Pfeifer D, Gao J, Adell G, Sun XF: Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:1143-1148.
13. Wallin A, Svanvik J, Adell G, Sun XF: Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:452-458.
14. Losi L, Ponti G, Gregorio CD, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, de Leon MP: Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006;202:663-670.
15. Jimenez-Anula J, Luque RJ, Gaforio JJ, Delgado M: Prognostic value of invasive growth pattern in sporadic colorectal cancer. Cir Esp 2005;77:337-342.
16. Meyer JS: Growth and cell kinetic measurements in human tumors. Pathol Annu 1981;16:53-81.
17. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
18. Stephens BJ, Han H, Gokhale V, Von Hoff DD: PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005;4:653-661.
19. Reid TS, Terry KL, Casey PJ, Beese LS: Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004;343:417-433.
20. Fiordalisi JJ, Keller PJ, Cox AD: PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 2006;66:3153-3161.
21. Gao J, Arbman G, Reader A, Sun XF: Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 2004;6:796-801.
22. Sun XF: p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 2002;8:165-170.
23. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B: Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369-1373.